CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

They also found that after the extra chromosome was removed, genes tied to nervous system development were more active and ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high ...

Rating upgraded from 65 to 76 Thursday — a welcome improvement, but still shy of the 80 or higher score you look for. Please ...

CRISPR Therapeutics is a biotech company that borrows its name from the groundbreaking gene editing technology CRISPR. As of last year, the company has earned FDA approval for a CRISPR-based treatment ...

CRISPR Therapeutics (NASDAQ:CRSP) operates within the biotechnology segment, which remains active across key indices like the ...

CRISPR Therapeutics (NasdaqGM:CRSP) recently announced updates on its in vivo cardiovascular disease programs, marking significant progress in trials for CTX310™ and CTX320™. The company's shares ...

Back in 1900 the life expectancy of people with Down Syndrome was 9 years. In 1984, it was 28 years, today it's leveled off ...

Plants face simultaneous abiotic (drought, salinity, heat) and biotic (pathogens, pests) stresses in natural and agricultural ...